ClinicalTrials.gg
RecruitingNCT07688278DENT-PCUpdated Jul 7, 2026

HbA1c Screening in Dental Care and Primary Care Referral in Patients With Advanced Periodontitis

An interventional study of Point-of-care HbA1c screening and Conditional standardized primary care referral in Periodontitis, Adult and Prediabetes / Type 2 Diabetes, sponsored by Region Skane. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Region Skane · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate whether HbA1c screening can be performed in dental care to detect elevated blood glucose in patients with advanced periodontitis and support referral to primary care.

Periodontitis is a common chronic inflammatory disease affecting the supporting tissues of the teeth. Advanced periodontitis is associated with prediabetes, type 2 diabetes and cardiovascular disease. The relationship between periodontitis and diabetes is bidirectional: diabetes increases the risk and severity of periodontitis, while periodontal inflammation may contribute to impaired glucose regulation. Patients with advanced periodontitis may therefore represent a group at increased risk of undetected elevated blood glucose. Many of these patients visit dental care regularly but may not otherwise be reached by structured medical prevention.

This is a cross-sectional observational feasibility study conducted in public dental clinics in Skåne, Sweden, in collaboration with primary care. Adult patients aged 18 years or older with advanced periodontitis, defined as periodontitis stage 3-4 or grade B/C, will be invited to participate during a routine dental visit. Patients with previously diagnosed diabetes will not be included.

After informed consent, participants will complete or update a health declaration and undergo capillary HbA1c testing at the dental clinic using a validated point-of-care instrument. Participants will receive their test result. Those with HbA1c ≥42 mmol/mol will receive standardized information and be referred to their listed primary care centre for further diagnostic assessment and preventive follow-up according to routine clinical practice.

The study will assess how feasible this pathway is in routine dental care. Outcomes include participation rate, successful HbA1c testing, time required for study procedures, prevalence of elevated HbA1c, proportion referred to primary care, completed primary care follow-up within six months, dropout and costs. Follow-up data will be collected from medical records and regional registers.

The study may provide a practical model for collaboration between dental care and primary care, with the long-term aim of improving early detection of prediabetes and diabetes and strengthening preventive care for patients with advanced periodontitis.

02

Conditions studied

  • Periodontitis, Adult
  • Prediabetes / Type 2 Diabetes
03

In context

Chronic Periodontitis

378 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.

This study's planned enrollment of 600 is above the median of 46 across 308 interventional studies indexed under Chronic Periodontitis.

Browse Chronic Periodontitis studies →

Lead sponsor

Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Advanced periodontitis, defined as stage 3-4 periodontitis or grade B/C periodontitis according to clinical and radiographic assessment during routine dental care.
  • Ability to understand study information and provide .

Exclusion criteria

Exclusion Criteria:

  • Previously diagnosed diabetes mellitus.
  • Inability to provide , for example due to severe mental disorder or markedly impaired health status as judged by the clinical staff.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    HbA1c Screening in Dental Care

    Adult patients with advanced periodontitis undergo point-of-care HbA1c screening during a routine dental care visit. Patients with HbA1c ≥42 mmol/mol receive standardized information and are referred to primary care for further assessment and preventive follow-up.

    Diagnostic Test: Point-of-care HbA1c screening · Other: Conditional standardized primary care referral

Interventions

  • Diagnostic testPoint-of-care HbA1c screening

    All participants undergo capillary HbA1c testing at the dental clinic using a validated point-of-care instrument. Test results are provided to the participant during the visit.

  • OtherConditional standardized primary care referral

    Participants with HbA1c ≥42 mmol/mol receive standardized information about the elevated test result and are referred to their listed primary care centre for further diagnostic assessment and preventive follow-up according to routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Participation rate

    Number of participants included out of those who meet the inclusion criteria. Reasons for non-participation will be recorded in free text.

    Time frame: 6 months

Secondary outcomes

  1. Proportion of participants with HbA1c 42 mmol/mol or higher.

    Proportion of participants with HbA1c 42 mmol/mol or higher

    Time frame: 6 months

  2. Proportion of patients undergoing blood pressure examination at follow-up in primary care

    Through review of medical records at the patient's primary health care center, assessment of proportion of patients undergoing blood pressure examination.

    Time frame: 6 months

  3. Proportion of patients undergoing blood lipid laboratory samples

    Through review of medical records in primary care, assessment of proportion of patients undergoing blood lipid laboratory sample.

    Time frame: 6 months

  4. Diagnosis at follow-up

    Diagnosis registered at the follow-up in primary care

    Time frame: 6 months

  5. Proportion of patients receiving lifestyle advice at follow-up

    Through review of medical records at follow-up in primary care, assessment of proportion of patients receiving advice on lifestyle habits.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Folktandvården Skåne AB
    Skåne, Sweden
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.

Of 89 non-industry interventional studies with no phase under Chronic Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 24. This study's planned 12 months is below that.

Counting every sponsor, half of 90 studies reached it within 15 months; a quarter within 10 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jul 7, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07688278
Lead sponsor
Region Skane
Collaborators
Folktandvården Skåne AB
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jul 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Susanna Calling
Contact
susanna.calling@med.lu.se
+46724640728
Peter Nymberg
Contact
peter.nymberg@med.lu.se

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion